Valeo Financial Advisors LLC Purchases Shares of 1,794 Biogen Inc. $BIIB

Valeo Financial Advisors LLC purchased a new stake in Biogen Inc. (NASDAQ:BIIB) in the second quarter, Holdings Channel.com reports. The institutional investor purchased 1,794 shares of the biotechnology company’s stock, valued at approximately $225,000.

Several other institutional investors have also recently made changes to their positions in BIIB. Opal Wealth Advisors LLC purchased a new position in shares of Biogen during the 1st quarter valued at approximately $26,000. Vision Financial Markets LLC acquired a new stake in Biogen during the first quarter valued at $27,000. Greykasell Wealth Strategies Inc. purchased a new stake in shares of Biogen during the 1st quarter worth about $27,000. Zions Bancorporation National Association UT purchased a new stake in shares of Biogen during the 1st quarter worth about $29,000. Finally, Private Trust Co. NA boosted its stake in shares of Biogen by 74.8% during the 1st quarter. Private Trust Co. NA now owns 229 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 98 shares in the last quarter. 87.93% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 517 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the transaction, the insider directly owned 5,772 shares in the company, valued at $770,850.60. The trade was a 8.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.18% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Rothschild & Co Redburn upped their price target on Biogen from $149.00 to $150.00 and gave the stock a “neutral” rating in a report on Monday, October 6th. Truist Financial initiated coverage on Biogen in a research note on Monday, July 21st. They set a “hold” rating and a $142.00 target price for the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Biogen in a research note on Wednesday. Morgan Stanley boosted their price target on shares of Biogen from $144.00 to $149.00 and gave the stock an “equal weight” rating in a report on Friday. Finally, Jefferies Financial Group began coverage on shares of Biogen in a report on Thursday, September 25th. They set a “buy” rating and a $190.00 price objective on the stock. Eleven investment analysts have rated the stock with a Buy rating, nineteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Biogen presently has a consensus rating of “Hold” and a consensus target price of $180.15.

Biogen Price Performance

Shares of NASDAQ BIIB opened at $146.57 on Friday. The firm has a 50-day simple moving average of $140.21 and a 200-day simple moving average of $131.23. The stock has a market capitalization of $21.49 billion, a price-to-earnings ratio of 14.01, a price-to-earnings-growth ratio of 1.18 and a beta of 0.13. The company has a quick ratio of 1.79, a current ratio of 2.50 and a debt-to-equity ratio of 0.36. Biogen Inc. has a 52 week low of $110.04 and a 52 week high of $194.13.

Biogen (NASDAQ:BIIB) last issued its earnings results on Thursday, July 31st. The biotechnology company reported $5.47 EPS for the quarter, beating analysts’ consensus estimates of $3.93 by $1.54. Biogen had a net margin of 15.31% and a return on equity of 13.85%. The business had revenue of $2.65 billion during the quarter, compared to analysts’ expectations of $2.32 billion. During the same period in the prior year, the business earned $5.28 earnings per share. The company’s quarterly revenue was up 7.3% compared to the same quarter last year. Biogen has set its FY 2025 guidance at 15.500-16.000 EPS. On average, equities analysts predict that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.